SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
9 - Grade/differentiation unknown, not stated, or not applicable
Chronic myelomonocytic leukemia in transformation
Chronic myelomonocytic leukemia, NOS
Chronic myelomonocytic leukemia, Type I
Chronic myelomonocytic leukemia, Type II
Chronic myelomonocytic syndrome
CMML with eosinophilia
Subacute myelomonocytic leukemia
CMML is a clonal disorder of a bone marrow stem cell, in which monocytosis is a major defining feature. The clinical, hematologic and morphologic features of CMML are heterogeneous, and vary along a spectrum from predominantly myelodysplastic to mainly myeloproliferative in nature.
A slowly progressing type of myelodysplastic/myeloproliferative disease in which too many myelomonocytes (a type of white blood cell) are in the bone marrow, crowding out other normal blood cells, such as white blood cells, red blood cells and platelets. Also called chronic myelomonocytic leukemia.
The peripheral blood and bone marrow are always involved. The spleen, liver, skin and lymph nodes are the most common sites of extramedullary infiltration. The peripheral blood has persistent monocytosis. There are fewer than 20% blasts in the peripheral blood and bone marrow. The physician will run tests to exclude the BCR-ABL1 fusion gene, the rearrangement of PDGFRA or PDGFRB. The physician uses the information from these tests to do a diagnosis of exclusion (clinical diagnosis) of Chronic myelomonocytic leukemia.